Literature DB >> 17426225

Serum indicators for the diagnosis of pneumocystis pneumonia.

Sadatomo Tasaka1, Naoki Hasegawa, Seiki Kobayashi, Wakako Yamada, Tomoyasu Nishimura, Tsutomu Takeuchi, Akitoshi Ishizaka.   

Abstract

BACKGROUND: The diagnosis of pneumocystis pneumonia (PCP) is difficult because it requires microscopic examination to identify pneumocystis from induced sputum or BAL fluid. STUDY
OBJECTIVE: To evaluate the usefulness of four serum markers-lactate dehydrogenase (LDH), (1-->3) beta-D-glucan (beta-D-glucan), KL-6, and C-reactive protein (CRP)-in the diagnosis of PCP.
DESIGN: Case-control retrospective study. PATIENTS AND MEASUREMENTS: We reviewed the medical records of 295 consecutive patients who underwent BAL for the diagnosis of PCP. Differential cell counts in BAL fluid and serum levels of LDH, beta-D-glucan, KL-6, and CRP were examined. Oxygenation index was determined using arterial oxygen tension and inspiratory oxygen concentration.
RESULTS: Based on the microscopic examination of BAL fluid, 57 patients were PCP positive and 238 patients were PCP negative. There were no significant differences in cell count or differentials in BAL fluid between the positive and negative cases. Serum levels of LDH, beta-D-glucan, and KL-6 were significantly higher in PCP-positive patients (p < 0.01). Receiver operating characteristic curves suggest that beta-D-glucan was the most reliable indicator. The cut-off level of beta-D-glucan was estimated to be 31.1 pg/mL, with which the positive and negative predictive values were 0.610 and 0.980, respectively. In PCP-positive patients, the oxygenation index was decreased and correlated with LDH. Both LDH and beta-D-glucan levels were correlated with the proportion of neutrophils in BAL fluid.
CONCLUSIONS: Serum beta-D-glucan is a reliable marker for the diagnosis of PCP. Since BAL procedure is invasive, measuring beta-D-glucan should be considered as a primary modality for a diagnosis of PCP, especially for patients with severe respiratory failure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426225     DOI: 10.1378/chest.06-1467

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  63 in total

Review 1.  Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis.

Authors:  Akira Onishi; Daisuke Sugiyama; Yoshinori Kogata; Jun Saegusa; Takeshi Sugimoto; Seiji Kawano; Akio Morinobu; Kunihiro Nishimura; Shunichi Kumagai
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

Review 2.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

3.  Clinical characteristics and prognosis of community-acquired pneumonia in autoimmune disease-induced immunocompromised host: A retrospective observational study.

Authors:  Zhong-Shu Kuang; Yi-Lin Yang; Wei Wei; Jian-Li Wang; Xiang-Yu Long; Ke-Yong Li; Chao-Yang Tong; Zhan Sun; Zhen-Ju Song
Journal:  World J Emerg Med       Date:  2020

Review 4.  The Japanese experience with biologic therapies for rheumatoid arthritis.

Authors:  Tsutomu Takeuchi; Hideto Kameda
Journal:  Nat Rev Rheumatol       Date:  2010-09-28       Impact factor: 20.543

5.  Differential diagnosis of pulmonary infections in immunocompromised patients using high-resolution computed tomography.

Authors:  Yoshie Kunihiro; Nobuyuki Tanaka; Reo Kawano; Toshiaki Yujiri; Makoto Kubo; Kazuhiro Ueda; Toshikazu Gondo; Taiga Kobayashi; Tsuneo Matsumoto
Journal:  Eur Radiol       Date:  2019-05-06       Impact factor: 5.315

6.  Elevated serum beta-D-glucan levels in immunocompromised children with clinical suspicion for Pneumocystis jirovecii pneumonia.

Authors:  Blanca E Gonzalez; Luis A Faverio; Francisco M Marty; Craig MacArthur; Robin B Churchill
Journal:  Clin Vaccine Immunol       Date:  2011-05-04

7.  Characterization of Pneumocystis jirovecii pneumonia at three tertiary comprehensive hospitals in southern China.

Authors:  Yan-Hui Chen; Xue-Yao Fang; Yue-Ting Li; Yan-Ling Liu; Ya-Ping Hang; Yan-Ping Xiao; Xing-Wei Cao; Qiao-Shi Zhong; Long-Hua Hu
Journal:  Braz J Microbiol       Date:  2020-05-03       Impact factor: 2.476

8.  S-1-induced lung injury combined with pneumocystis pneumonia.

Authors:  Shuichi Yano
Journal:  BMJ Case Rep       Date:  2013-02-04

9.  Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of pneumocystis pneumonia.

Authors:  Michael J Linke; Alan Ashbaugh; Margaret S Collins; Keeley Lynch; Melanie T Cushion
Journal:  Infect Immun       Date:  2013-01-14       Impact factor: 3.441

10.  Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study.

Authors:  Yasuo Shimizu; Noriaki Sunaga; Kunio Dobashi; Makoto Fueki; Naoto Fueki; Sohei Makino; Masatomo Mori
Journal:  BMC Infect Dis       Date:  2009-04-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.